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Secondary mitral regurgitation (MR) also known as the 
'functional' MR, is not primarily due to underlying valve 
pathology. It is due to left ventricular dysfunction either 
secondary to idiopathic dilated cardiomyopathy or due to 
underlying coronary artery disease (CAD). Regional or 
global left ventricular (LV) systolic dysfunction and 
adverse LV remodelling can cause restricted leaflet 
motion and failure of leaflet coaptation resulting in MR.1 
Thus, the mechanism is largely ventricular rather than 
valvular. MR burdens the LV with a volume overload state 
that leads to a series of compensatory myocardial and 
circulatory adjustments. Eventually, the myocardium fails, 
the ventricle decompensates, and the patient exhibits 
signs of heart failure. It has been strongly associated with 
decreased quality of life, increased rate of hospitalization 
for heart failure, and shortened survival.2,3 Hence, the 
prognosis among patients with heart failure and 
secondary mitral regurgitation is extremely poor 
associated with high mortality rates. 
In the remote past, the only option to treat secondary MR 
was to treat the underlying etiology. Guideline-directed 
medical therapy (GDMT) and cardiac resynchronization 
therapy (CRT) provided symptomatic relief, improved the 
left ventricular function, and in some patients, it lessened 
the severity of mitral regurgitation.4 As correction of valve 
in case of primary MR improve outcomes, the contrary 
was not true in case of secondary MR as the valve was 
structurally normal. Hence, neither percutaneous or 
surgical repair nor surgical replacement of the mitral 
valve had shown to lower the rate of hospitalization or 
death associated with secondary mitral regurgitation.4 
Percutaneous repair by MitraClip is a transcatheter 
technology based on the surgical Alfieri edge-to-edge 
repair, which involves suturing together the middle 
segments of the anterior and posterior mitral valve 
leaflets, thereby creating a "double orifice" mitral 
regurgitant area.5 The MitraClip system utilizes a cobalt 
chromium clip covered with a polypropylene fabric that 
grasps the leaflet and reduces mitral regurgitation (MR) 
by increasing the coaptation between the regurgitant 
valve leaflets. In some cases, a second clip may be 
required to adequately reduce the MR severity toward a 
goal of final regurgitant severity <2+.6  
In The Endovascular Valve Edge-to-Edge Repair Study 
(EVEREST) II trial, transcatheter mitral-leaflet 
approximation with the MitraClip device was found to be 
safer than surgical mitral-valve repair but was not as 
effective in reducing the severity of mitral regurgitation.7 
In August, 2018; Mitra FR trial was published that showed 
that in patients with secondary MR, the rate of death or 
unplanned hospitalization for heart failure at 1 year did 
not differ significantly between patients who underwent 
percutaneous mitral-valve repair in addition to receiving 
medical therapy and those who received medical therapy 
alone.8 But the recently published landmark trial "COAPT 
- Cardiovascular Outcomes Assessment of the MitraClip 
Percutaneous Therapy for Heart Failure Patients with 
Functional Mitral Regurgitation trial contradicted the 
Mitra FR trial. These investigators showed that in patients 
with moderate to severe or severe secondary mitral 
regurgitation that remained symptomatic despite the use 
of maximal tolerated doses of GDMT, transcatheter mitral-
valve repair resulted in a lower rate of hospitalization for 
heart failure and lower all-cause mortality within 24 
months of follow-up than medical therapy alone.9 
COAPT trial is a randomized controlled trial that had two 
groups; one group was assigned to GDMT while the other 
group had mitra clip in place in addition to the GDMT. 
With long follow up of 2 years, the rate of hospitalization 
for heart failure significantly reduced in the group 
receiving mitra clip. Similarly, all-cause mortality was also 
significantly decreased in the device group. (Figure A and 
B) The rate of freedom from device related complications 
at 12 months was significantly lower as compared to both 
the EVEREST-II trial and MITRA FR trial. One of the reasons 
why this trial was successful was that the procedural 
success rates for MitraClip implantation was 98%, with 
immediate achievement of a MR grade of 2+ or lower 
(moderate MR or less) in 95% of the patients. This was also 
durable over time with only 0.9% of patients reporting 
3+MR (severe MR) at 2 years follow up compared to 14% 
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as reported in previous trials.10 The results from COAPT 
trial can have a significant impact on the management of 
patients with secondary MR. 
In conclusion, COAPT trial showed that in patients with 
moderate-to-severe or severe secondary mitral 
regurgitation with heart failure who remained 
symptomatic despite the use of maximal doses of GDMT, 
transcatheter mitral valve repair (MitraClip) resulted in a 
lower rate of hospitalization for heart failure, lower 
mortality, and better quality of life and functional capacity 
within 24 months of follow-up than medical therapy 
alone. 
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Figure: A shows rates of hospitalization for heart failure were significantly reduced at 24 months in the device group compared to the control group Similarly Panel. B, shows decrease 
mortality in device group compared to the control group.
